ClinicalTrials.gg
RecruitingNCT05593497SNAREUpdated Oct 26, 2026

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

A Phase 2 interventional study of Capivasertib and abiraterone acetate in High-Risk Prostate Cancer, sponsored by VA Office of Research and Development. Recruiting at 9 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 26, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing capivasertib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 3 of them phase 3. capivasertib · Prostatic Neoplasms.

Planned enrollment
7th of 10
30 · median 238
Started
2024
the only one that year
Phase 2
3 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
VA Office of Research and Development

Among the 10 studies testing capivasertib in Prostatic Neoplasms, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 2, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 10 studies testing capivasertib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capivasertib

capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing capivasertib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.

Read the detailed description

Prostate cancer is the second leading cause of cancer deaths in men in the United States. Prostate cancer treatment options are historically based on clinical stage, prostate specific antigen (PSA) blood test, and tumor grade. High-risk prostate cancers treated surgically commonly exhibit loss of the phosphatase and tensin homologue (PTEN) tumor suppressor gene, which leads to increased activity of the AKT signaling pathway. PTEN loss is associated with higher rates of prostate cancer recurrence, metastasis, and cancer mortality. Manipulation of androgens and androgen receptor (AR) to reduce mortality has been the focus of prostate cancer systemic therapy for decades; however, PTEN loss is a lead mechanism for prostate cancer resistance to AR directed therapy and development of castrate resistant prostate cancer. Pre-clinical research identified a reciprocal feedback regulation between the PTEN/AKT signaling axis and the Androgen Receptor (AR) signaling axis. Thus, blockade of both pathways may be necessary in tumors with PTEN loss.

This study will change standard localized treatment (radical prostatectomy alone) by conducting a single arm Phase II trial combining intensified androgen deprivation (iADT; abiraterone and leuprolide) with an AKT inhibitor (capivasertib) prior to radical prostatectomy among high-risk localized prostate cancers with PTEN loss. The goal is that early precision treatment of aggressive disease will result minimal residual cancer at the time of prostatectomy, and subsequently improved cancer outcomes.

Eligible patients with high-risk prostate cancer exhibiting 10% PTEN staining by IHC will be exposed to a 4-week run-in of iADT, followed by dedicated research biopsy of the tumor to be used for correlative research, then treated with 16 weeks of combined iADT with AKT inhibition (capivasertib). Patients will then undergo radical prostatectomy as standard of care, with assessment of pathological response (pT0 or minimal residual disease) via central pathology review.

03

Conditions studied

  • High-Risk Prostate Cancer

Browse trials for

Keywords

  • Veterans
  • prostate cancer
  • PTEN protein
  • prostatectomy
  • neoadjuvant therapy
  • abiraterone acetate
  • capivasertib
  • leuprolide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : provision of signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Members of all races and ethnic groups will be included.
  3. Participants must have confirmed non- adenocarcinoma of the prostate
  4. (a) Any one of the following three high risk features:

    • Gleason sum >7 (ISUP Grade Group >3)
    • Clinical stage T3 (resectable), per American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition
    • Prostate-specific antigen (PSA) > 20 nanograms per milliliter (ng/ml) oSubjects who meet high risk criteria solely by PSA (i.e., stage \<T3 AND Gleason sum less than or equal to 7) must have a progression-free probability after radical prostatectomy that is less than or equal to 50% at 5 years as estimated by the Memorial Sloan Kettering (MSK) pre-radical prostatectomy nomogram: https://www.mskcc.org/nomograms/prostate/pre_op (b) Subjects not meeting high risk criteria that have the following combination may be screened for inclusion:
    • Gleason score 4+3=7 (ISUP Grade Group 3) AND
    • Estimated progression-free probability after radical prostatectomy that is less than or equal to 50% at 5 years by MSK nomogram
  5. No definitive evidence of metastasis on nuclear bone scan (required on all subjects)
  6. No evidence of lymph nodes > 2 centimeter (cm) in diameter on pelvic computed tomography (CT) scan (scan only required in patients with a PSA > 20 ng/ml)
  7. Prostatectomy with extended lymph node dissection planned as primary therapy

    • The subject had a discussion with a clinician about other options, such as radiotherapy, and elected to undergo surgical treatment
    • The subject has been offered consultation with radiation oncology and declined consultation or radiation treatment, or determined it was not in best medical interest
  8. Be willing to provide tissue from a diagnostic core or excisional biopsy of a tumor lesion obtained up to 6 months/180 days prior to initiation of treatment on Day 1. Subjects for whom samples cannot be provided (e.g., inaccessible or subject safety concern) may submit an older archived specimen only upon agreement from the Sponsor-Investigator.
  9. Tumor tissue must be provided for biomarker analysis. Phosphatase and tensin homologue (PTEN) immunohistochemistry (IHC) staining must be less than or equal to 10% as determined by the central lab. If insufficient tumor tissue content is provided for analysis, acquisition of additional archived tumor tissue (block and /or slides) for the biomarker analysis is required
  10. Have a performance status of 0 or 1 on the Performance Scale with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  11. of greater than 10 years per the treating physician
  12. Minimum body weight of 45 kilogram (kg) with minimum (BMI) of 18.5
  13. Non-sterile men who are not totally sexually abstinent (i.e., refraining from heterosexual intercourse during the entire period of risk associated with study interventions) and intend to be sexually active with a women of partner must use a condom upon entering the study and until 16 weeks after the last dose of capivasertib. should be considered in females' partners of men taking capivasertib who are of childbearing potential
  14. Able and willing to swallow and retain oral medication
  15. Demonstrate adequate organ function as defined by laboratory parameters including ANC, , , transaminases, albumin, , or , and INR (unless anticoagulated, then therapeutic range is acceptable). All screening labs should be performed within 30 days of treatment initiation

Exclusion criteria

Exclusion Criteria:

  1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant and active bleeding diseases, uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
  2. Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining .
  3. Known to have active hepatitis infection, positive antibody, virus surface antigen or hepatitis B virus core antibody, at screening. Known to have (HIV) with a \< 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months. Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).

    Known history of drug or alcohol abuse within 6 months of screening.

  4. Prior prostate cancer treatment including:

    • Anti-androgen therapy including orchiectomy, luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, ketoconazole, estrogen therapy (Short-term ADT allowed, less than or equal to 2 months)
    • Radiation (external beam or brachytherapy)
    • Cytotoxic chemotherapy
    • Focal or ablative therapy
    • Any experimental therapy for treatment of prostate cancer.
  5. History of another primary except for malignancy treated with curative intent with no known active disease greater than or equal to 5 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy
  6. Any of the following cardiac criteria:

    • Mean resting interval (QTc) > 470 msec obtained from 3 consecutive ECGs
    • Any abnormalities in rhythm, conduction or morphology of resting (e.g., complete left bundle branch block, third-degree heart block)
    • Medical history significant for arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted to enter the study
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
    • Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or or Class II to IV heart failure or cardiac measurement of \< 50%
    • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade less than or equal to 2
    • Uncontrolled hypotension - systolic blood pressure (SBP) \<90 mmHg and/or diastolic blood pressure (DBP) \<50 mmHg
    • Uncontrolled hypertension (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 95 mmHg).
    • Cardiac ejection fraction outside institutional range of normal or \<50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive).
  7. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    • Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment
    • greater than or equal to 8.0% (63.9 mmol/mol)
  8. nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib and abiraterone.
  9. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  10. Previous bone marrow transplant or solid organ transplant
  11. Received major surgery within 6 weeks prior to screening, or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study except for prostatectomy; they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  12. Is currently participating and receiving study therapy, or has participated in a study of an investigational agent or study drugs within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment
  13. Has had a prior anti-cancer monoclonal antibody (mAb) within 30 days prior to study Day 1 or who has not recovered (i.e., less than or equal to Grade 1 or at baseline) from adverse events due to agents administered more than 30 days earlier.
  14. Has had prior chemotherapy, immunotherapy, targeted small molecule therapy, medication (other than ), or radiation therapy within 30 days prior to study Day 1, or who has not recovered (i.e., less than or equal to Grade 1 or at baseline) from adverse events due to a previously administered agent.

    Note: Subjects with less than or equal to Grade 2 neuropathy are an exception to this criterion and may qualify for the study if 0-1.

    Note: A longer washout may be required for drugs with a long half-life (e.g., 30 days or 5 half-lives, whichever is longer)

  15. Treatment with any of the following:

    • Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
    • Potent inhibitors or inducers of within 2 weeks before the start of study treatment (3 weeks for St John's wort), or sensitive substrates of CYP3A4, CYP2C9 and/or CYP2D6 with a narrow therapeutic window within 1 week before the start of study treatment
    • Drugs known to prolong the QT interval within 5 half-lives of the first dose of study treatment
    • Any concomitant medication that may interfere with abiraterone safety and efficacy based on the prescribing information of abiraterone and local clinical guidelines
  16. History of to active or inactive of capivasertib, abiraterone, or drugs with a similar chemical structure or class.
  17. Any restriction or based on the local prescribing information that would prohibit the use of abiraterone and leuprolide.
  18. Is unable to undergo research related as this is necessary to complete translational study objectives
  19. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Single Arm

    neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy

    Drug: Capivasertib · Drug: abiraterone acetate

Interventions

  • 400 milligrams (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).

  • Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5 milligrams po daily. Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib.

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response or Minimal Residual Disease (MRD)

    No cancer detected on radical prostatectomy specimen, or minimal residual disease 5 millimeters (mm).

    Time frame: 5 months

Secondary outcomes

  1. Surgical Complications

    Incidence of Surgical Complications \[ Time Frame: 4 months \] Clavien-Dindo Classification of Surgical Complications compared to historical department incidence rates within 90 days after surgery.

    Time frame: 5 months + 90 days

  2. ERG Expression and Pathologic Response

    No cancer detected on radical prostatectomy specimen, or minimal residual disease 5 millimeters (mm), stratified by normal versus increased ERG expression by immunohistochemistry in prostatectomy specimen

    Time frame: 5 months

Other outcomes

  1. Treatment related adverse events

    Grade 3 or higher adverse event (AE) possibly related or related to any of three treatment drugs (capivasertib, abiraterone, leuprolide) per CTCAE v5, evaluated up until 90 days after prostatectomy

    Time frame: 5 months + 90 days

07

Study locations

8 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2028, 53 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 53 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion May 2027 → Oct 2028 and completion Aug 2027 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 25, 2022
StartActual
May 31, 2024
Primary completionEst.
Oct 31, 2028was May 2027
CompletionEst.
Jan 31, 2029was Aug 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Jesse Brown VA Medical Center, Chicago, IL · Chicago, United StatesNot yet recruiting→Recruiting
  • Michael E. DeBakey VA Medical Center, Houston, TX · Houston, United StatesNot yet recruiting→Recruiting
across 2 updates, Oct 5, 2026 – Oct 26, 2026
Primary completion
May 1, 2027→Oct 31, 2028
Oct 26, 2026
Study completion
Aug 1, 2027→Jan 31, 2029
Oct 26, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPathologic Complete Response or Minimal Residual Disease (MRD): how it is measured was reworded
Oct 5, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionERG Expression and Pathologic Response: how it is measured was reworded
Oct 5, 2026
Contact
Study contact changed: added l•••@va.gov · •••1060. See the current contact
Oct 26, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • VA Portland Health Care System, Portland, OR · Portland, United StatesContact l•••@va.gov · •••1060→A•••@va.gov · •••8262
  • Michael E. DeBakey VA Medical Center, Houston, TX · Houston, United StatesContact added t•••@va.gov · •••7939
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Michael E. DeBakey VA Medical Center, Houston, TX is now Recruiting
    Primary completion May 1, 2027→Oct 31, 2028
    Study completion Aug 1, 2027→Jan 31, 2029
    Contact Study contact changed: added l•••@va.gov · •••1060. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • VA Portland Health Care System, Portland, OR · Portland, United StatesContact l•••@va.gov · •••1060→A•••@va.gov · •••8262
    • Michael E. DeBakey VA Medical Center, Houston, TX · Houston, United StatesContact added t•••@va.gov · •••7939
    + 3 other changes: verification date, conditions and criteria formatting
  2. Oct 5, 2026
    Jesse Brown VA Medical Center, Chicago, IL is now Recruiting
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPathologic Complete Response or Minimal Residual Disease (MRD): how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionERG Expression and Pathologic Response: how it is measured was reworded
    + 4 other changes: identifiers, verification date, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05593497
Responsible party
Sponsor
First posted
Oct 25, 2022
Start date
May 31, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Ryan P Kopp, MD
Contact
ryan.kopp@va.gov
(503) 220-8262 ext. 56128
Laura Onstad, RN
Contact
laura.onstad@va.gov
(503) 721-1060
Ryan P Kopp, MD
principal investigator · VA Portland Health Care System, Portland, OR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capivasertib · Abiraterone Acetate

Start the discussion